Dr Patrick Bowden is committed to providing comprehensive, patient-centred cancer care. He is a highly experienced doctor who remains at the forefront of cutting-edge radiation therapy techniques and clinical research.
Dr Patrick Bowden has 20 years’ experience as a consultant radiation oncologist and is based at Icon Cancer Centre Richmond, Freemasons, Moreland, Mulgrave and Canberra. He has continually been at the forefront of new technologies in radiation therapy treatment throughout his oncology career. Dr Bowden is a leading specialist in the use of intensity modulated radiation therapy [IMRT] and stereotactic radiation therapy for treatment of early metastatic disease.
After establishing his radiation oncology career at Peter MacCallum Cancer Centre, he became director of the Tattersall’s Cancer Centre in 2007, the private arm of Peter MacCallum Cancer Centre. In 2011 he was appointed as the inaugural Director of Epworth Radiation Oncology. In this role he built Australia’s largest stereotactic radiation therapy service including a clinical trial institute and integrated oncology services at Epworth Freemasons. In 2016 the South West Regional Cancer Centre in Warrnambool was established under his directorship before his integral role in the transition of Epworth Radiation Oncology to Icon Cancer Centre.
Dr Bowden is actively involved in education, medical leadership, research and clinical trials. He was previously a member of Epworth Medical Advisory Committee from 2007-2016 (maximum allowed 9-year tenure). Outside radiation oncology, he is the Chairman of Access Telehealth; Australia’s largest provider of free consultations to patients in rural and remote areas.
Dr Bowden has been active in numerous clinical trials and acted as principal investigator in key studies investigating radiation therapy treatments for lung, cervix and prostate cancers. In July 2019, his world-leading study TRANSFORM was published in the International Journal of Cancer, evaluating the efficacy of stereotactic radiation therapy for oligometastatic prostate cancer. In June 2021, his PINPOINT study investigating the use of Calypso guidance beacons to reduce prostate radiation therapy side effects was published in the World Journal of Urology. Both Australian studies with the support of Epworth Medical Foundation and EJ Whitten Foundation were the world’s largest clinical trials of their kind.
His clinical experience covers a broad range of solid tumour malignancies, with a special interest in urological cancers (including prostate cancer), gastrointestinal cancer, central nervous system (CNS) and metastatic cancers.